Dr. Kim is in charge of leading business strategy planning and business development at ILIAS Biologics; based on his 15 years of experience in the biopharmaceutical and healthcare industry, he contributes to ILIAS becoming a global biopharmaceutical company. Prior to joining ILIAS, Dr. Kim was in charge of Business Development and IP Portfolio strategy at MEDINNO Inc., a Korean biopharmaceutical company. Dr. Kim also worked at public institutions and research-oriented hospital such as Korea Research Institute of Bioscience and Biotechnology (KRIBB), Samsung Medical Center (SMC), and Korea Health Industry Development Institute (KHIDI), where he demonstrated outstanding performance in charge of the global healthcare technology and trends analysis, licensing in/out, business strategy, and R&D planning-evaluation-management.
Dr. Kim received his bachelor's degree from Korea University and earned Ph.D. in Technology Management, Economics and Policy Program (TEMEP) from Seoul National University. Dr. Kim is also Korea Certified Valuation Analyst (KCVA).